Blog

- Andrew Celentano

Vantis Vascular Receives FDA Clearance for 6F CrossFAST Microcatheter

Vantis Vascular, a San Jose, California-based privately held medical technology company developing performance-driven technologies for coronary interventions, has received the U.S. Food and Drug Administration (FDA) 510(k) clearance for a new 6 French (6F) model of its CrossFAST Integrated Microcatheter Advanced Delivery System.

Read More »

UCB announces U.S. FDA approval for ZILBRYSQ® (zilucoplan) autoinjector

ATLANTA, Oct. 20, 2026 /PRNewswire/ — UCB (Euronext Brussels: UCB), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved the first self-administered once-daily autoinjector administration option for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive with ZILBRYSQ® (zilucoplan).¹ The autoinjector is designed to help simplify self-administration of ZILBRYSQ, offering patients another administration option and a more convenient treatment experience.2,3

Read More »